Drug Trial Radar · NCT00907296
Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
402
Actual
Start
Sep 2, 2009
Primary completion
Mar 6, 2012
Study completion May 10, 2013
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- UCB Pharma
- First posted
- May 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).
Conditions
- Fracture Healing
Interventions
RomosozumabBiological
Administered by subcutaneous injection
PlaceboDrug
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Radiographic HealingTime frame: 52 weeks
Locations
103 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Orange, California
Research Site
Aurora, Colorado
Research Site
Denver, Colorado
Research Site
Jacksonville, Florida
Research Site
Indianapolis, Indiana
Research Site
Detroit, Michigan
Research Site
St Louis, Missouri
Research Site
Brooklyn, New York
Research Site
Rochester, New York
Research Site
Altoona, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Columbia, South Carolina
Research Site
Sandy City, Utah
Research Site
Geelong, Victoria, Australia
Research Site
Parkville, Victoria, Australia
Research Site
Blagoevgrad, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Red Deer, Alberta, Canada
Research Site
Ajax, Ontario, Canada
Research Site
Thunder Bay, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Windsor, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Ã…rhus C, Denmark
Research Site
Hvidovre, Denmark
Research Site
København NV, Denmark
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Lille, France
Research Site
Marseille, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Aachen, Germany
Research Site
Hamburg, Germany
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.